The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Personalized circulating tumor DNA for minimal residual disease and dynamic assessment in patients undergoing neoadjuvant chemotherapy for breast cancer: Preliminary analysis from MSK-LINC.
 
Hong-Kyu Kim
Stock and Other Ownership Interests - Berits Inc.
Research Funding - GeneCker
 
Julia Ah-Reum An
No Relationships to Disclose
 
Christopher Gareth Smith
Employment - NeoGenomics Laboratories
 
Jisun KIM
Stock and Other Ownership Interests - Genopeaks
Research Funding - Genopeaks (Inst)
 
Luc Cabel
No Relationships to Disclose
 
Enrico Moiso
No Relationships to Disclose
 
Emanuela Ferraro
No Relationships to Disclose
 
Anton Safonov
No Relationships to Disclose
 
Konner Nelson
No Relationships to Disclose
 
Kathleen Szuhany
No Relationships to Disclose
 
Joshua Z. Drago
Honoraria - Intellisphere
Consulting or Advisory Role - AmMax Bio; AstraZeneca; GenagonTherapeutics; Launchpad Therapeutics; NuProbe
Research Funding - AstraZeneca (Inst); Bolt Biotherapeutics (Inst)
 
Larry Norton
Stock and Other Ownership Interests - Codagenix
Honoraria - ABC7 Global Alliance Conference; Blackrock QLS Advisors; BrightEdge-CancerRx Meeting at MIT; Bristol-Myers Squibb/Celgene; Codagenix; Cold Spring Harbor Laboratory; CSHL; Dominguez V. United States; Isom Lecture Seminar at UTSW; MSK Pharma; NCI Reviews; TGH Cancer Institute; Third Annual NYOH Breast Cancer Symposium; Transgender and non-binary Breast Cancer Education; UNC Breast Spore EAB Meeting
Consulting or Advisory Role - Agenus; Blackrock, Inc; Codagenix; IMMIX BIOPHARMA, INC.
Expert Testimony - Dominguez V. United States
 
Amy Xu
No Relationships to Disclose
 
Howard I. Scher
Honoraria - Elsevier; Physicans' Education Resource
Consulting or Advisory Role - AIQ Global; Bayer; Genzyme; Janssen Research & Development; Pfizer; Promontory Therapeutics; Regeneron; WIRB-Copernicus Group
Research Funding - AIQ Solutions (Inst); Biodesix (Inst); Epic Sciences (Inst); Janssen (Inst); Thermofisher Scientific Biomarkers (Inst)
Patents, Royalties, Other Intellectual Property - Elucida Oncology - Intellectual Property Rights
Travel, Accommodations, Expenses - Bayer; Biodesix; Epic Sciences; Promontory Therapeutics; Prostate Cancer Foundation; WIRB-Copernicus Group
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Odyssey Biosciences; Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Boxer Capital; Inivata; Lilly; Novartis; Paige.ai; Prelude Therapeutics; SAGA Diagnostics; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Paige.ai (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Novartis Institutes for BioMedical Research
Other Relationship - Peerview; Targeted Oncology; WebMD
(OPTIONAL) Uncompensated Relationships - Odyssey Biosciences; Totus Medicines
 
Atif J. Khan
Employment - Memorial Sloan-Kettering Cancer Center
Stock and Other Ownership Interests - Novavax; Xtrava Health
Research Funding - Clovis Oncology; Merck KGaA; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Use patent for the drug riluzole awarded to Rutgers University with me as inventor.
 
Bob T. Li
Research Funding - Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Amgen
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - Artios (Inst); AstraZeneca (Inst); Merck (Inst); Pfizer (Inst); Zenith Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - AstraZeneca; Clinical Care Options; Clinical Education Alliance; MJH Healthcare Holdings, LLC; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; GlaxoSmithKline; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
George Plitas
Consulting or Advisory Role - Merck; PAIGE.AI; Takeda; Tizona Therapeutics, Inc.; Trishula Therapeutics
Speakers' Bureau - Merck
Research Funding - Takeda
Patents, Royalties, Other Intellectual Property - Anti-CCR8 agents
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Loxo/Lilly; Myriad Genetics; NeoGenomics Laboratories; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - AstraZeneca (Inst); Biovica (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Hologic/Biotheranostics (Inst); Illumina (Inst); Invitae (Inst); Myriad Genetics (Inst); NeoGenomics Laboratories (Inst); Novartis (Inst); Tempus (Inst)